Letrozole (112809-51-5) video
Letrozole (112809-51-5) Description
Letrozole is an oral non-steroidal aromatase inhibitor, brand name is Femara. It is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.
Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Letrozole blocks production of estrogens in this way by competitive, reversible binding to the heme of its cytochrome P450 unit. The action is specific, and letrozole does not reduce production of mineralo- or corticosteroids. In contrast, the antiestrogenic action of tamoxifen, the major medical therapy prior to the arrival of aromatase inhibitors, is due to its interfering with the estrogen receptor, rather than inhibiting estrogen production.
Letrozole has shown to reduce estrogen levels by 98 percent while raising testosterone levels. The anti-estrogen action of letrozole is preferred by athletes and bodybuilders for use during a steroid cycle to reduce bloating due to excess water retention and prevent the formation of gynecomastia related breast tissue that is a side effect of some anabolic steroids.
Letrozole (112809-51-5) Specifications
|Chemical Name||Femara; ,4′-((1h-1,2,4-triazol-1-yl)methylene)dibenzonitrile; Letrozol|
|Drug Class||aromatase inhibitor|
|Molecular Weight||285.31 g/mol|
|Monoisotopic Mass||285.101 g/mol|
|Melting Point||184-185 °C|
|Freezing Point||No data available|
|Biological Half-Life||2 days|
|Color||While or off-while powder|
|Solubility||Water Solubility 0.0799 mg/mL|
|Storage Temperature||-20°C Freezer|
|Application||1. used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause.